Ovarian Carcinoma — Trials

Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

895 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 270
Recruiting: 140
Ph III recruiting: 16
Growth YoY: +23.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (145)

clinicaltrialsPublishedShowing 1–16 of 16 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07708753	A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	recruiting	Phase 3	460	CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY	1	Sep 23, 2026	clinicaltrials
NCT06915025	Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer(OVATION-3)	recruiting	Phase 3	500	ImunonINDUSTRY